AMA Ed Hub Logo

Learn more on naloxone from AMA Ed Hub™
Red JAMA Logo

Learn more on naloxone from JAMA Network™
2025 Annual Meeting of the HOD

Learn more on naloxone from PolicyFinder
Poster for naloxone

How to administer Naloxone

2 Min Read
Clear Search
Narcan kit
·
3 Min Read

FDA naloxone guidance helps harm-reduction groups’ work to save lives

Learn how new clarity from the FDA on burdensome requirements for bulk purchase of naloxone aid underserved communities.

Behavioral Health
·
1 Min Read

New guidance on naloxone to strengthen work of harm reduction groups

The guidance announced today offers regulatory clarity for harm reduction organizations to purchase naloxone so more will be distributed in communities.

Press Releases
Person in grocery aisle
·
4 Min Read

Removing naloxone’s Rx status is an essential step to save lives

As the drug-overdose epidemic worsens, there is no moral, medical or safety-related reason for keeping naloxone locked under prescription regulations.

Behavioral Health
·
2 Min Read

AMA urges Administration to remove naloxone from behind the counter

Removing the prescription status of naloxone as an essential step to save lives from opioid-related overdose, helps to make naloxone available to patients.

Press Releases
Exterior of an emergency room entrance
·
4 Min Read

M1s help spot emergency patients who can benefit from naloxone

Learn how first-year medical students can add value and learn about addiction medicine by screening patients to ID those at risk of an opioid-related overdose.

ChangeMedEd Initiative
Outdoor Emergency Room sign
·
4 Min Read

Embracing harm reduction in the emergency department

Learn about work by Phoenix emergency physicians to get naloxone directly into the hands of patients at risk of overdose.

Behavioral Health
·
3 Min Read

Dec. 3, 2021: State Advocacy Update

AMA urges nation’s naloxone manufactures to make product OTC and more in the latest State Advocacy Update.

Advocacy Update
·
1 Min Read

AMA statement on FDA decision on naloxone nasal

AMA commends FDA’s approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose.

Press Releases
·
1 Min Read

AMA applauds FDA for requiring naloxone information on opioid labels

The new labeling can serve as a starting point for discussion between patients and physicians about risks and benefits associated with opioids.

Press Releases